- Pfizer (PFE) offered to purchase AstraZeneca (AZN) in January for £46.61 ($76.62) a share in cash and stock, the U.S. company said, with the proposal representing a 30% premium on AstraZeneca's shares at the time.
- After "limited high-level discussions, AstraZeneca declined to pursue negotiations," Pfizer said. The latter again contacted AstraZeneca on Saturday about a deal and the latter again "declined to engage."
- Pfizer is now "considering its options" and will continue to offer a premium on AstraZeneca's shares, which closed at £40.80 on Friday for a market cap of £51.47B. (PR)
From other sites
at CNBC.com (Jun 1, 2015)
at CNBC.com (May 28, 2015)
at CNBC.com (Apr 10, 2015)
at CNBC.com (Mar 23, 2015)
at CNBC.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs